Moringa Acquisition Corp
MACAW
NASDAQ Capital Market0.15
USD
-0.01
- -
Moringa Acquisition Corp
MACAW
(NASDAQ Capital Market)
Recent
price
0.15
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Moringa Acquisition Corp is a special purpose acquisition company (SPAC) primarily engaged in effecting mergers, share exchanges, asset acquisitions, share purchases, reorganizations, or other business combinations with technology-based companies, particularly those related to Israel. Founded in 2020 and headquartered in New York, New York, the company did not operate traditional business lines independently but aimed to serve as a public acquisition vehicle to facilitate access to growth-stage companies. The core recent major change for Moringa Acquisition Corp occurred in 2024 when it completed a business combination with Silexion Therapeutics Ltd., a clinical-stage, oncology-focused biotechnology company based in Modi’in, Israel. Silexion specializes in developing innovative treatments for difficult-to-treat solid tumor cancers characterized by the mutated KRAS oncogene, with a lead siRNA therapy candidate aimed at locally advanced pancreatic cancer. This merger, finalized in August 2024, transformed Moringa from a SPAC into an operating biotech company rebranded as Silexion Therapeutics Corp, with its shares trading on Nasdaq under the ticker symbols SLN and SLXNW. Following the business combination, Moringa's business profile shifted significantly from a SPAC to a biotechnology firm focused on oncology therapeutics, including siRNA treatments for solid tumors driven by KRAS mutations. This strategic shift included new operational activities related to clinical drug development and preparing for further therapeutic advancements in cancer treatment. The transaction provided greater financial and strategic flexibility to Silexion to pursue its mission of developing next-generation oncology treatment options. Moringa Acquisition Corp’s geographic footprint includes the United States and Israel, reflecting its corporate headquarters in New York and its operational base through Silexion in Israel. The company targets the biotechnology and pharmaceutical industry segments, serving healthcare providers, research institutions, and cancer patients seeking innovative treatments. In summary, Moringa Acquisition Corp transformed from a special purpose acquisition company focused on technology acquisitions into Silexion Therapeutics Corp, an actively operating clinical-stage biotech company developing oncology therapies, as a result of its 2024 reverse merger with Silexion Therapeutics Ltd. This change marks a major strategic evolution from a SPAC structure to an operating biotech entity with specific oncology product candidates and ongoing clinical development programs.